They are present in the M1–M6 subtypes (French American British (FAB) classification of AML), but absent in AML M0 and patients with t(8;21), inv(16), t(15;17), or CCAAT/enhancer-binding protein-α (CEBPA) mutations [15]. The gene discussed is CEBPA; the disease is acute myeloid leukemia.